Showing 3501-3510 of 5661 results for "".
- Lindus Health and Thirty Madison Complete Enrollment of Personalized Dermatology Care Pilot Studyhttps://practicaldermatology.com/news/lindus-health-and-thirty-madison-complete-enrollment-of-personalized-dermatology-care-pilot-study/2462182/Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, announced the completion of enrolment of a pilot study to assess the effectiveness of their personalized dermatology telemedicine platform Facet. The novel teleh
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflamma
- Dial Gives Back to Teachers With DonorsChoose, TeacherListshttps://practicaldermatology.com/news/dial-gives-back-to-teachers-with-donorschoose-teacherlists/2462170/For the third consecutive year, Dial is partnering with DonorsChoose, an education-focused nonprofit that supports public sc
- Biosimilar News: Samsung Bioepis Secures US License Date for Proposed Stelara Biosimilarhttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-secures-us-license-date-for-proposed-stelara-biosimilar/2462165/Samsung Bioepis Co., Ltd. signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara&nb
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Derm-Biome Pharmaceuticals, Massachusetts General Hospital Partner for Skin Cancer Study of New Topical Rxhttps://practicaldermatology.com/news/derm-biome-pharmaceuticals-massachusetts-general-hospital-partner-for-skin-cancer-study-of-new-topical-rx/2462157/Derm-Biome Pharmaceuticals Inc. is collaborating with Massachusetts General Hospital for a study looking at Derm-Biome’s second-generation topical treatment for precancerous skin conditions and non-melanoma skin cancers. The topical is highly sel
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that
- Ichthyosis Linked to Mood Disordershttps://practicaldermatology.com/news/ichthyosis-linked-to-mood-disorders/2462139/People living with Ichthyosis may be at higher risk for mental health conditions like depression and anxiety, according to a recent study in the Journal of the American Academy of Dermatology. Re
- Amorepacific Receives the CES Innovation Award for 'Lipcure Beam'https://practicaldermatology.com/news/amorepacific-receives-the-ces-innovation-award-for-lipcure-beam/2462138/Amorepacific's 'Lipcure Beam' technology received the Consumer Electronics Show 2024 (CES 2024) Innovation Award, marking the company's fifth consecutive win at the tech event. The 'Lipcure Beam' combines lip diagnosis, care, and makeup capabilities in one unit.
- Unmet Needs in Dermatology: NFX-179 Topical Gel May Shrink Cutaneous Neurofibromas in NF1 Patientshttps://practicaldermatology.com/news/unmet-needs-in-dermatology-nfx-179-topical-gel-may-shrink-cutaneous-neurofibromas-in-nf1-patients/2462134/NFX‑179 Gel produced a statistically significant improvement over vehicle in the shrinkage of cutaneous neurofibromas in people with neurofibromatosis type 1 (NF1), according to positive topline results from a Phase 2b clinical trial. Cutaneous neurofibromas (cNFs) appear in over 9